Valbiotis Releases its Letter to Shareholders for 2021
09 Septembre 2021 - 5:40PM
Business Wire
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible)
(Paris:ALVAL), a Research and Development company committed to
scientific innovation for preventing and combating metabolic
diseases, announces the release of the latest issue of its Letter
to Shareholders, for 2021.
In this Letter to Shareholders:
- A message from Sébastien PELTIER, CEO, Chairman of the
Valbiotis Management Board;
- A summary of the Company’s latest news;
- An update on the progress of the active substances development
plan.
The Letter to shareholders can be consulted in the "Investors"
area of the Valbiotis website, in the "Shareholder area"
section.
To receive the next editions, shareholders are invited to
register here.
About Valbiotis Valbiotis is a Research & Development
company committed to scientific innovation for the treatment and
prevention of metabolic diseases in response to unmet medical
needs. Valbiotis has adopted an innovative approach, aiming to
revolutionize healthcare by developing a new class of health
nutrition products designed to reduce the risk of major metabolic
diseases, based on a multi-target approach enabled by the use of
plant-based ingredients. Its products are intended to be licensed
to players in the health sector. Created at the beginning of 2014
in La Rochelle, the Company has forged numerous partnerships with
leading academic centers. The Company has established three sites
in France – Périgny, La Rochelle (17) and Riom (63) – and a
subsidiary in Quebec City (Canada). Valbiotis is a member of the
"BPI Excellence" network and has been recognized as an "Innovative
Company" by the BPI label. Valbiotis has also been awarded "Young
Innovative Company" status and has received major financial support
from the European Union for its research programs via the European
Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible
company. For more information about Valbiotis, please visit:
www.valbiotis.com
Name: Valbiotis ISIN code: FR0013254851
Mnemonic code: ALVAL EnterNext© PEA-PME 150
This press release contains forward-looking statements about
Valbiotis’ objectives. Valbiotis considers that these projections
are based on rational hypotheses and the information available to
Valbiotis at the present time. However, in no way does this
constitute a guarantee of future performance, and these projections
may be affected by changes in economic conditions and financial
markets, as well as certain risks and uncertainties, including
those described in the Valbiotis Universal Registration Document
approved by the French Financial Markets Regulator (AMF) on July
27, 2021 (application number R 21-039). This document is available
on the Company’s website (www.valbiotis.com). This press release
and the information it contains do not constitute an offer to sell
or subscribe, or a solicitation to purchase or subscribe to
Valbiotis’ shares or financial securities in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210909005474/en/
Corporate communication / Valbiotis Carole ROCHER / Marc
DELAUNAY +33 5 46 28 62 58 media@valbiotis.com
Financial communication / Actifin Stéphane RUIZ +33 1 56 88 11
14 sruiz@actifin.fr
Valbiotis (EU:ALVAL)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Valbiotis (EU:ALVAL)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024